These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 29214723

  • 21. Validation of a focused echocardiographic training program in first opinion practice.
    Dickson D, Harris J, Chang CH, Patteson M, Hezzell MJ.
    J Vet Intern Med; 2022 Nov; 36(6):1913-1920. PubMed ID: 36221315
    [Abstract] [Full Text] [Related]

  • 22. Long-term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy.
    Vollmar AC, Fox PR.
    J Vet Intern Med; 2016 Nov; 30(2):553-9. PubMed ID: 26936799
    [Abstract] [Full Text] [Related]

  • 23. Pimobendan in heart failure therapy--a silver bullet?
    Gordon SG, Miller MW, Saunders AB.
    J Am Anim Hosp Assoc; 2006 Nov; 42(2):90-3. PubMed ID: 16527909
    [Abstract] [Full Text] [Related]

  • 24. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN, Hirakawa A, Sonobe J, Otaki H, Sakakibara N, Seewald W, Forster S.
    J Vet Sci; 2018 Jan 31; 19(1):117-128. PubMed ID: 28693297
    [Abstract] [Full Text] [Related]

  • 25. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E, King JN, Strehlau G, White RV.
    Can Vet J; 2011 Nov 31; 52(11):1219-25. PubMed ID: 22547843
    [Abstract] [Full Text] [Related]

  • 26. Effect of pimobendan on left atrial function in dogs with preclinical myxomatous mitral valve disease.
    Sarcinella F, Neves J, Maddox TW, Hodgkiss-Geere HM, Bode EF, Dukes-McEwan J.
    Open Vet J; 2020 Jan 31; 9(4):375-383. PubMed ID: 32042661
    [Abstract] [Full Text] [Related]

  • 27. Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.
    Tidholm A, Höglund K, Häggström J, Ljungvall I.
    J Vet Intern Med; 2015 Jan 31; 29(6):1510-7. PubMed ID: 26365438
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of a mitral regurgitation severity index to predict long-term outcome in dogs with myxomatous mitral valve disease.
    Vereb M, Atkins CE, Adin D, Blondel T, Coffman M, Lee S, Guillot E, Ward JL.
    J Vet Intern Med; 2024 Jan 31; 38(1):51-60. PubMed ID: 37909399
    [Abstract] [Full Text] [Related]

  • 29. Left ventricular twist and circumferential strain in dogs with myxomatous mitral valve disease.
    Zois NE, Olsen NT, Moesgaard SG, Rasmussen CE, Falk T, Häggström J, Pedersen HD, Møller JE, Olsen LH.
    J Vet Intern Med; 2013 Jan 31; 27(4):875-83. PubMed ID: 23731222
    [Abstract] [Full Text] [Related]

  • 30. Radial and longitudinal strain and strain rate assessed by speckle-tracking echocardiography in dogs with myxomatous mitral valve disease.
    Zois NE, Tidholm A, Nägga KM, Moesgaard SG, Rasmussen CE, Falk T, Häggström J, Pedersen HD, Åblad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Jan 31; 26(6):1309-19. PubMed ID: 23113772
    [Abstract] [Full Text] [Related]

  • 31. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 31; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ, Fine DM, Thombs LA, Gorelick JJ, Durham HE.
    J Vet Intern Med; 2009 Aug 31; 23(6):1190-6. PubMed ID: 19780931
    [Abstract] [Full Text] [Related]

  • 33. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE, Falk T, Zois NE, Moesgaard SG, Häggström J, Pedersen HD, Ablad B, Nilsen HY, Olsen LH.
    J Vet Intern Med; 2012 Aug 31; 26(1):76-84. PubMed ID: 22151356
    [Abstract] [Full Text] [Related]

  • 34. Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study.
    Schober KE, Rush JE, Luis Fuentes V, Glaus T, Summerfield NJ, Wright K, Lehmkuhl L, Wess G, Sayer MP, Loureiro J, MacGregor J, Mohren N.
    J Vet Intern Med; 2021 Mar 31; 35(2):789-800. PubMed ID: 33543810
    [Abstract] [Full Text] [Related]

  • 35. Left Atrial Strain at Different Stages of Myxomatous Mitral Valve Disease in Dogs.
    Nakamura K, Kawamoto S, Osuga T, Morita T, Sasaki N, Morishita K, Ohta H, Takiguchi M.
    J Vet Intern Med; 2017 Mar 31; 31(2):316-325. PubMed ID: 28145607
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetics of pimobendan after oral administration to dogs with myxomatous mitral valve disease.
    McManamey AK, DeFrancesco TC, Meurs KM, Papich MG.
    J Vet Intern Med; 2023 Mar 31; 37(6):2003-2010. PubMed ID: 37776546
    [Abstract] [Full Text] [Related]

  • 37. Current use of pimobendan in canine patients with heart disease.
    Boswood A.
    Vet Clin North Am Small Anim Pract; 2010 Jul 31; 40(4):571-80. PubMed ID: 20610012
    [Abstract] [Full Text] [Related]

  • 38. Usefulness of conventional and tissue Doppler echocardiography to predict congestive heart failure in dogs with myxomatous mitral valve disease.
    Kim JH, Park HM.
    J Vet Intern Med; 2015 Jan 31; 29(1):132-40. PubMed ID: 25270196
    [Abstract] [Full Text] [Related]

  • 39. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
    Eriksson AS, Häggström J, Pedersen HD, Hansson K, Järvinen AK, Haukka J, Kvart C.
    J Vet Cardiol; 2014 Sep 31; 16(3):141-54. PubMed ID: 25130405
    [Abstract] [Full Text] [Related]

  • 40. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG, Saunders AB, Roland RM, Winter RL, Drourr L, Achen SE, Hariu CD, Fries RC, Boggess MM, Miller MW.
    J Am Vet Med Assoc; 2012 Jul 01; 241(1):89-94. PubMed ID: 22720992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.